Next Phase Newsletter

A corporate venture fund of a pharmaceutical company has their main office in the US. With its inaugural fund, the firm seeks to invest in technologies that are complementary to the parent pharma company’s R&D activities. The firm seeks to invest $5-7M as initial investment, and can invest up to $20M over the company’s lifecycle. The firm will focus on investing in companies based in the US, Western Europe, and Japan. 
 
The firm focuses on investing in therapeutics, platform technologies, and digital technologies. In therapeutics, the firm has a strong interest in cell/gene therapy, protein degraders, and covalent binders, as well as platform technologies including any platforms that can find or develop drugs across multiple therapeutic areas. Within digital technologies, the firm primarily seeks applications that help with target identification and drug design, accelerating drug discovery and development. The firm is not seeking clinical and patient-centric investments, and does not invest in medical devices or diagnostics. In terms of stage of development, the firm focuses on pre-clinical and early clinical stage opportunities. 
 
The firm does not have specific company or management team requirements. The firm does not lead investments and does not require board representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A newly founded venture capital firm headquartered in the US is interested in Seed stage companies that focus on gene tech (DNA, RNA, proteins, and cells). Typical check size is expected to be around USD $500k and the firm will typically not lead rounds. Companies can have their headquarters elsewhere; however, the firm requires companies to be U.S. Incorporated. 
 
In terms of healthcare, the firm is interested in diagnostics using DNA, RNA, or proteins, cell and gene therapy, engineered vaccines, antibiotics, longevity and health span improvements, software and data, bioinformatic solutions, platforms, and AI-powered solutions. The firm is not interested in small molecules and medical devices. 

The firm does not have strict company or management team requirements. The firm does not require to take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital headquartered in Europe was built on foundation of an incubator which has been operating since 2017. The firm invests in early-stage companies in the pre-seed and seed rounds, offering up to €250K tickets, with the possibility of follow-on investments. The firm invests globally, with a focus on European businesses. The firm offers convertibles and priced rounds, where the firm typically follows (or co-leads), and can assign a technical and business mentor to each team, tailoring the cooperation to the needs of each startup. 
 
The firm is sector-agnostic but exclusively focused on disruptive AI-driven solutions. The firm requires a testable prototype or proof-of-concept (POC) and initial business traction and is happy to look into B2B or B2C. 
 
The firm requires companies to have an established team of founders.  

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A global private equity and venture capital firm with offices in the UK and the US has been investing in life sciences and healthcare for over 30 years and manages approximately $3.7 billion in AUM across several funds. The firm focuses on four key areas: therapeutics, dementia, healthcare growth, and medtech. For therapeutics, the firm is stage-agnostic and invests across all stages, from seed to crossover rounds approaching IPO. It also engages in company creation and building, allowing it to invest at very early stages in those cases. The average check size ranges from $5 million to $25 million, with the possibility of follow-on investments. While the firm prefers to lead, it is open to co-investing and will consider taking board positions on a case-by-case basis. As a transatlantic firm, the firm considers opportunities globally, with a focus on Europe and the US.

The firm invests in therapeutics, healthcare, and medtech. The therapeutics team is agnostic to both modalities and indications, considering a wide range of opportunities within the traditional therapeutics space. The firm is also stage-agnostic, investing at any stage from pre-clinical to late phases. In addition, the firm manages a separate fund which focuses exclusively on companies developing or enabling novel therapeutics for dementia.

The firm does not have specific requirements for the company or management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

An early-stage investment fund supporting innovation across human health, food, agriculture, and climate is backed by sole LP, one of the world’s largest dairy exporters and producer of human nutrition products. The fund brings experience and expertise across both investing & operating in the Food and BioTech, ClimateTech and AgTech sectors. Its operating model allows access into the nearly 100 years of capability, ingenuity, manufacturing and distribution experience within its parent corporation, while maintaining the agility and responsiveness to be a strong partner to start-ups and innovators in the space.

The fund typically invests in seed to Series A opportunities, though remains open to companies at later stages. The average check size ranges from $2M to $5M USD, with the ability to go beyond this. The fund is open to both leading and co-investing and will consider board positions on a case-by-case basis. The fund is actively seeking opportunities globally and is open to deal structures beyond equity investments, such as co-development and in-licensing, especially for technologies that align strategically with it parent corporation.

The fund is generally interested in technologies that use nutrients to improve human health, such as those targeting the microbiome, cognitive function, sleep, and more. Areas of interest include the microbiome, alternative ingredients, and the application of molecules and proteins. The fund places a strong emphasis on data. In terms of development stages, the fund is open to working with companies from the pre-clinical stage through all phases of clinical and commercial development. The fund does not have specific requirements for the company or management team. However, the fund seeks founding teams with passion and strong technical expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.

The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.

The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A boutique venture capital firm headquartered in Boston with a global outreach and epicenter in Dubai has invested alongside Tier 1 VCs in 12 companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies.

The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity. The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.